{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-005637","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2024-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.605878+00:00","generated_at":"2026-06-07T01:00:48.729484+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"First pediatric patient dosed with TSHA-102 in REVEAL Phase 1/2 trial for Rett syndrome","bullets":["First pediatric patient (female, 5-8 years, stage 3 Rett syndrome) dosed at RUSH University Medical Center.","MHRA authorized UK CTA for TSHA-102 in pediatric patients, expanding REVEAL into the UK.","Initial safety and efficacy data for cohort one (low dose, n=3) expected in mid-2024.","TSHA-102 uses miRARE technology to mediate MECP2 expression on a cell-by-cell basis.","TSHA-102 also has FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-005637","json":"https://secwatch.observer/filing/0001193125-24-005637.json","markdown":"https://secwatch.observer/filing/0001193125-24-005637.md","text":"https://secwatch.observer/filing/0001193125-24-005637.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312524005637/0001193125-24-005637-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312524005637/d674544d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:00:48.729484+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}